Dr Anna Durbin | Associate Professor
Johns Hopkins Bloomberg School of Public Health

Dr Anna Durbin, Associate Professor, Johns Hopkins Bloomberg School of Public Health

Dr. Durbin received her Bachelor of Science in Pharmacy from the University of Michigan, Ann Arbor Michigan and her M.D. from Wayne State University in Detroit Michigan. She completed her residency in Internal Medicine at the Detroit Medical Center, Wayne State University where she was Chief Medical Resident at Detroit Receiving Hospital.  She then completed fellowship training in Infectious Diseases at the Detroit Medical Center.  Following her fellowship in infectious diseases, Dr. Durbin became a Medical Officer at the Laboratory of Infectious Diseases at the National Institutes of Health where she spent 5 years using recombinant DNA technology to develop novel live attenuated respiratory virus vaccines.  She left the NIH to become a tenure-track faculty in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health where she is currently as associate professor.  She is the Principal Investigator of a National Institutes of Health contract to evaluate novel malaria vaccines and is the co-principal investigator for a contract to evaluate vaccines and antimicrobials in adults and pediatric subjects.  She has served as the Principal Investigator for numerous clinical trials evaluating the safety and immunogenicity novel live attenuated dengue vaccine candidates.  These trials have led to the identification of a live attenuated tetravalent dengue vaccine that will soon begin evaluation in flavivirus-naïve and flavivirus-experienced volunteers in Brazil and Thailand.  Dr. Durbin received a National Institutes of Health Merit Award in 2005, a National Institutes of Health Director’s Award in 2011 and the Instituto Butantan medal, Sao Paulo Brazil, in 2013.  She has published more than 60 peer-reviewed papers.


Day 2, April 8 @ 14:40

Panel: Unravelling dengue vaccine safety concerns: To what extend could they have been predicted?

  • Use of controlled human infection models
  • Need for complete assessment of viremia induced by the vaccine
  • The importance of balanced infectivity in live attenuated vaccines and balanced efficacy across age groups and sero-status
  • Surveillance:
    • Need for improved surveillance systems where dengue vaccine is introduced
    • How long should active surveillance continue?
    • Collection of blood samples – baseline & routinely scheduled collections
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates